The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
Open accessAbstract
We have developed a series of in vitro models with which to evaluate the biological activity of estrogen receptor (ER) agonists and antagonists. Using a protease digestion assay we show that the conformational changes induced within ER are distinct for agonists and antagonists. However, this assay is unable to discriminate between pure antagonists like ICI164,384 and partial agonists such as 4-OH tamoxifen or keoxifene. Using a chimeric ER-VP16 construct, we demonstrate that both pure antagonists and partial agonists deliver ER to its DNA target within cells. However, the ability of the DNA-bound receptor to activate transcription in the presence of a given antagonist is dependent on cell and promoter context. These data, suggesting functional differences among ER antagonists, were confirmed by additional experiments demonstrating that their ability to modulate the transcriptional activity of a series of ER mutants is dramatically different. Depending on the cell and promoter context and the particular ER form expressed, 4-OH tamoxifen and the related compound, keoxifene, functioned as partial agonists. Importantly, the transcriptional profiles of these two compounds were dissimilar, suggesting that they are functionally different from each other and from ICI164,384, which does not display agonist activity under any context examined. Our results reveal functional differences between these clinically important antiestrogens and suggest that the distinct biologies manifest by these compounds in vivo relate to their ability to differentially regulate ER function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Jilka, R. L., Hangoc, G., Girasole, G., Passeri, G., Williams, D. C., Abrams, J. S., Boyce, B., Broxmeyer, H., & Manolagas, S. C. (1992) · Science · doi:10.1126/science.1621100 · Cited by 1,442
The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
(1991) · PubMed · Cited by 1,101
The human estrogen receptor has two independent nonacidic transcriptional activation functions
Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer, E., & Chambon, P. (1989) · Cell · doi:10.1016/0092-8674(89)90031-7 · Cited by 1,048
Tzukerman, M. T. (1994) · Molecular Endocrinology · doi:10.1210/me.8.1.21 · Cited by 671
The Effect of Postmenopausal Estrogen Therapy on Bone Density in Elderly Women
Felson, D. T., Zhang, Y., Hannan, M. T., Kiel, D. P., Wilson, P., & Anderson, J. J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199310143291601 · Cited by 585
Steroid receptors and their associated proteins
Smith, D. F. (1993) · Molecular Endocrinology · doi:10.1210/me.7.1.4 · Cited by 545
Kedar, R., Bourne, T. H., Collins, W. P., Campbell, S., Powles, T. J., Ashley, S., & Cosgrove, D. O. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92466-x · Cited by 531
Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.
Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4037 · Cited by 465
Cited by
The Protective Effects of Estrogen on the Cardiovascular System
Mendelsohn, M. E., & Karas, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906103402306 · Cited by 3,103
ERβ: Identification and characterization of a novel human estrogen receptor
Mosselman, S., Polman, J., & Dijkema, R. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00782-x · Cited by 2,269
Nilsson, S., Mäkelä, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., & Gustafsson, J.-Å. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.4.1535 · Cited by 1,996
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767
Male reproductive health and environmental xenoestrogens.
Toppari, J., Larsen, J. C., Christiansen, P., Giwercman, A., Grandjean, P., Guillette, L. J., Jégou, B., Jensen, T. K., Jouannet, P., Keiding, N., et al. (1996) · Environmental Health Perspectives · doi:10.1289/ehp.96104s4741 · Cited by 1,403
The Multifaceted Mechanisms of Estradiol and Estrogen Receptor Signaling
Hall, J. M., Couse, J. F., & Korach, K. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100029200 · Cited by 1,208
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
Lamberts, S. W. J., van den Beld, A. W., & van der Lely, A.-J. (1997) · Science · doi:10.1126/science.278.5337.419 · Cited by 980
Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931
In vitro molecular mechanisms of bisphenol A action.
Wetherill, Y. B., Akingbemi, B. T., Kanno, J., McLachlan, J. A., Nadal, A., Sonnenschein, C., Watson, C. S., Zoeller, R. T., & Belcher, S. M. (2007) · Reproductive Toxicology · doi:10.1016/j.reprotox.2007.05.010 · Cited by 920
“The idea that ligands play an active role in ER function was proposed by McDonnell and others who demonstrated that different ligands induce distinct conformational changes in the ER, correlating with the observed diversity in transcriptional and biological responses [95–97].”
BackgroundBarkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J.-Å., & Nilsson, S. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.105 · Cited by 779
Basic Guide to the Mechanisms of Antiestrogen Action
Macgregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 694
Smith, C. S., Nawaz, Z., & O’Malley, B. W. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.657 · Cited by 662
Mechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
Lonard, D. M., Nawaz, Z., Smith, C. L., & O'Malley, B. W. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80259-2 · Cited by 562
Hong, H., Kohli, K., Garabedian, M. J., & Stallcup, M. R. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.5.2735 · Cited by 556
Katzenellenbogen, J. A. (1996) · Molecular Endocrinology · doi:10.1210/me.10.2.119 · Cited by 535
Manolagas, S. C. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.385 · Cited by 517
Compston, J. E. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.1.419 · Cited by 511
Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol
Gould, J. C., Leonard, L. S., Maness, S. C., Wagner, B. L., Conner, K., Zacharewski, T., Safe, S., McDonnell, D. P., & Gaido, K. W. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00084-7 · Cited by 510
Self-citationStructure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 499
Ovarian steroids and the brain: Implications for cognition and aging
McEwen, B. S., Alves, S. E., Bulloch, K., & Weiland, N. G. (1997) · Neurology · doi:10.1212/wnl.48.5_suppl_7.8s · Cited by 482
Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L. W., & Horwitz, K. B. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.693 · Cited by 478
The Estrogen Receptor β Subtype: A Novel Mediator of Estrogen Action in Neuroendocrine Systems
Kuiper, G. G. J. M., Shughrue, P. J., Merchenthaler, I., & Gustafsson, J.-Å. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0170 · Cited by 439
Functional Synergy between the Transcription Factor Sp1 and the Estrogen Receptor
Porter, W. W., Saville, B., Hoivik, D. J., & Safe, S. H. (1997) · Molecular Endocrinology · doi:10.1210/me.11.11.1569 · Cited by 428
Wijayaratne, A. L., & McDonnell, D. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 427
Self-citationLoss of ERβ expression as a common step in estrogen-dependent tumor progression
Bardin, A., Boulle, N., Lazennec, G., Vignon, F., & Pujol, P. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00800 · Cited by 417
Jordan, V. C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020449y · Cited by 414
Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β
Paige, L. A., Christensen, D. J., Grøn, H., Norris, J. D., Gottlin, E. B., Padilla, K. M., Chang, C.-Y., Ballas, L. M., Hamilton, P. T., McDonnell, D. P., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3999 · Cited by 412
Self-citationBerger, J., Leibowitz, M. D., Doebber, T. W., Elbrecht, A., Zhang, B., Zhou, G., Biswas, C., Cullinan, C. A., Hayes, N. S., Li, Y., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6718 · Cited by 410
ICI 182,780 (Faslodex?): Development of a novel, ?pure? antiestrogen
Howell, A., Osborne, C. K., Morris, C., & Wakeling, A. E. (2000) · Cancer · doi:10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6 · Cited by 408
Saville, B., Wormke, M., Wang, F., Nguyen, T., Enmark, E., Kuiper, G., Gustafsson, J.-Å., & Safe, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5379 · Cited by 401
Kuiper, G. G. J. M., & Gustafsson, J.-Å. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00413-4 · Cited by 400
Webb, P. M., Nguyen, P. T., Valentine, C. D., Lopez, G. N., Kwok, G. R., McInerney, E. M., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J.-Α., Nilsson, S. V., et al. (1999) · Molecular Endocrinology · doi:10.1210/me.13.10.1672 · Cited by 396
Giangrande, P. H., A. Kimbrel, E., Edwards, D. P., & McDonnell, D. P. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3102-3115.2000 · Cited by 376
Self-citationSelective Estrogen Receptor Modulators: Structure, Function, and Clinical Use
Osborne, C. K., Zhao, H. (., & Fuqua, S. A. W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3172 · Cited by 367
Structural Insights into the Mode of Action of a Pure Antiestrogen
Pike, A. C. W., Brzozowski, A. M., Walton, J., Hubbard, R. E., Thorsell, A.-G., Li, Y.-L., Gustafsson, J.-Å., & Carlquist, M. (2001) · Structure · doi:10.1016/s0969-2126(01)00568-8 · Cited by 347
Stepping backward to improve assessment of PCB congener toxicities.
Hansen, L. G. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106s1171 · Cited by 336
Kraus, W. L., & Kadonaga, J. T. (1998) · Genes & Development · doi:10.1101/gad.12.3.331 · Cited by 334
Berger, J. P., Petro, A. E., Macnaul, K. L., Kelly, L. J., Zhang, B. B., Richards, K., Elbrecht, A., Johnson, B. A., Zhou, G., Doebber, T. W., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0217 · Cited by 321
Petersen, D. N., Tkalcevic, G. T., Koza-Taylor, P. H., Turi, T. G., & Brown, T. A. (1998) · Endocrinology · doi:10.1210/endo.139.3.5840 · Cited by 310
Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action
Dutertre, M., & Smith, C. L. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38923-2 · Cited by 299
The Molecular Pharmacology of SERMs
McDonnell, D. P. (1999) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(99)00177-0 · Cited by 299
Self-citationHuman Estrogen Receptor β Binds DNA in a Manner Similar to and Dimerizes with Estrogen Receptor α
Pace, P., Taylor, J., Suntharalingam, S., Coombes, R. C., & Ali, S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25832 · Cited by 298
Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Komm, B. S., Kharode, Y. P., Bodine, P. V. N., Harris, H. A., Miller, C. P., & Lyttle, C. R. (2005) · Endocrinology · doi:10.1210/en.2005-0030 · Cited by 298
Coregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting
Hall, J. M. (2005) · Molecular Interventions · doi:10.1124/mi.5.6.7 · Cited by 295
Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2000) · Breast Cancer Research · doi:10.1186/bcr78 · Cited by 293
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer
Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., & _, _. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00857 · Cited by 286
Negro-Vilar, A. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.10.3459 · Cited by 282
Quantitative comparisons of in vitro assays for estrogenic activities.
Fang, H., Tong, W., Perkins, R., Soto, A. M., Prechtl, N. V., & Sheehan, D. M. (2000) · Environmental Health Perspectives · doi:10.1289/ehp.00108723 · Cited by 277
McInerney, E. M., Weis, K. E., Sun, J., Mosselman, S., & Katzenellenbogen, B. S. (1998) · Endocrinology · doi:10.1210/endo.139.11.6298 · Cited by 269
Htun, H., Holth, L. T., Walker, D., Davie, J. R., & Hager, G. L. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.2.471 · Cited by 261
Phosphorylation of Human Estrogen Receptor α by Protein Kinase A Regulates Dimerization
Chen, D., Pace, P. E., Coombes, R. C., & Ali, S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1002 · Cited by 260
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*
Jordan, V. C., & Morrow, M. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0368 · Cited by 258
Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins
Ma, H., Hong, H., Huang, S.-M., Irvine, R. A., Webb, P., Kushner, P. J., Coetzee, G. A., & Stallcup, M. R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6164 · Cited by 256
Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator.
McInerney, E. M., Tsai, M. J., O'Malley, B. W., & Katzenellenbogen, B. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.19.10069 · Cited by 256
Wagner, B. L., Norris, J. D., Knotts, T. A., Weigel, N. L., & McDonnell, D. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1369 · Cited by 255
Self-citationSelective estrogen receptor modulators: an update on recent clinical findings
Shelly, W., Draper, M. W., Krishnan, V., Wong, M., & Jaffe, R. B. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31816400d7 · Cited by 193
Gibson, D. A., & Saunders, P. T. K. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.026 · Cited by 107
Stepping Backward to Improve Assessment of PCB Congener Toxicities
Hansen, L. G. (1998) · Environmental Health Perspectives · doi:10.2307/3433919 · Cited by 336
Design of Conditionally Active STATs: Insights into STAT Activation and Gene Regulatory Function
Milocco, L. H., Haslam, J. A., Rosen, J., & Seidel, H. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2913 · Cited by 52
Endocrine-Disrupting Chemicals
Frye, C. A. (2014) · Vitamins & Hormones · doi:10.1016/b978-0-12-800095-3.00003-1 · Cited by 22
Metadata
- Authors
- McDonnell, D. P.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1995-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 659-669
- ISSN
- 0888-8809 (ISSN-L)
- OpenAlex
- W2015252965
- Cited by
- 526
- References
- 25
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.